BioSpace News Archive

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

Alexion Pharmaceuticals closed out its first quarter plans to seek regulatory approval for its paroxysmal nocturnal hemoglobinuria (PNH) treatment, ALXN1210, which is considered the successor to the company’s blockbuster blood-disorder drug Soliris.

The San Francisco Business Times and the Silicon Valley Business Journal pulled together to create a list of the Best Places to Work in the Bay Area. Hitting the list at number 23 for large companies is biotechnology company Amyris.

Mereo pulled its planned initial public offering (IPO) on the Nasdaq Global Market, saying market conditions were not in the best interests of its shareholders. The company’s statement is getting some pushback from investors and analysts.

Shares of Allergan have been in decline for more than a year and that has created an opening for some investors to begin rattling sabers about change at the company.

Every year for the last 32 years, Enrst & Young has awarded entrepreneurs in various categories, including Life Science, Consumer Products and Retail, Distribution and Manufacturing and other categories. The awards are given in June. The finalists have been announced. Here’s a look at some of the finalists and semi-finalists.

Paris-based Sanofi reported mixed first-quarter revenues, with net sales down 8.7 percent to 7,898 million euros. But Sanofi Genzyme sales were up 16.2 percent, mostly the result of its new immunology franchise.

The first quarter of 2018 for Vertex Pharmaceuticals was highlighted by the U.S. Food and Drug Administration’s February approval of Symdeko, a combination treatment for cystic fibrosis.

PruittHealth - Moultrie has proven its commitment to an ongoing and concentrated focus on patient-centered quality service delivery.

PruittHealth - Shepherd Hills completed a successful annual survey in late March, receiving no deficiencies.